The global TB vaccine treatment market is expected to grow at a significant CAGR during the forecast period. As per the World Health Organization (WHO), in 2020, an estimated 10 million people fell ill with tuberculosis (TB) globally, which includes 5.6 million men, 3.3 million women and 1.1 million children. Globally, the number of patients receiving TB prevention treatment climbed from 1 million in 2015 to 3.6 million in 2019. Government measures and international support to reduce tuberculosis prevalence is contributing to the growth of the global TB vaccine treatment market. As per the World Health Organization (WHO) global tuberculosis (TB) report 2021, in August 2021, there were 25 drugs in Phase I, Phase II, or Phase III trials for the treatment of drug-susceptible TB, MDR-TB, or TB infection.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/tb-vaccine-treatment-market
There are 16 new chemical entities, two accelerated regulatory approval medications, one drug recently approved by the US Food and Drug Administration under the limited population pathway for antibacterial and antifungal treatments, and six repurposed drugs among these drugs. Several combination regimens involving new or repurposed drugs, as well as host-directed therapy, are now in Phase II or Phase III trials. There were 14 vaccine candidates in clinical trials as of August 2021, with two in Phase I, eight in Phase II, and four in Phase III. The bacille Calmette-Guérin (BCG) vaccine is the only approved vaccination for TB prevention. The BCG vaccine, which was created about a century ago and is routinely used, prevent severe types of TB in children. Although results from a Phase II trial of the M72/AS01E candidate are promising, there is presently no vaccination that is effective in preventing TB disease in adults, either before or after exposure to TB infection.
To tackle TB, India has developed the National Strategic Plan (NSP) for TB Elimination 2017-2025, which accounts for half a million global TB mortality. India also established the India TB Research Consortium to promote the development of TB vaccines and medications. A considerable percentage of TB patients are seen in developed locations such as North America. According to the Centers for Disease Control and Prevention, 9,093 cases of TB were reported in the US in 2017. Each patient’s treatment costs for MDR-TB and XDR-TB were around $160,000 and $513,000, respectively. This in turn, is driving the demand for TB vaccines in the country.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Product
- Regions covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape: Merck & Co., Inc., Sanofi SA, and GlaxoSmithKline plc, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global TB Vaccine Treatment Market Report by Segment
By Product
- Immune Vaccine
- Therapy Vaccine
A full report of TB Vaccine Treatment Market is available at: https://www.omrglobal.com/industry-reports/tb-vaccine-treatment-market
TB Vaccine Treatment Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Merck & Co., Inc.
- Sanofi SA
- GlaxoSmithKline plc
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
